🔒 Encrypted & handled per our Privacy Policy
✓
You took Dupixent
Meeting these guidelines does not mean you have a valid claim. It means a participating law firm is likely to review it. That firm decides on its own whether to take your case. Some claims are turned down, and some recover nothing. Direct2Attorney cannot judge the legal merits of your case, give legal advice, or file anything for you.
Most states still allow recovery, reduced by your share of the blame. It is one of the most common reasons people never call — and one of the least justified.
— Educational
Dupixent works well for millions of people. Stopping it suddenly can cause a severe skin flare. For someone using it for asthma, stopping can be dangerous.
Nothing on this page is medical advice, and nothing here is a reason to skip a dose. If this page worries you, call your prescribing doctor and ask. That is a medical decision between you and your physician. It is completely separate from any legal question, and asking a lawyer never changes your treatment.
Dupixent is the brand name for dupilumab. It is a biologic, made by Sanofi and Regeneron and approved in 2017. It works by blocking two proteins in the immune system called IL-4 and IL-13, which drive the inflammation behind eczema and several other conditions.
The lawsuits are about a rare skin cancer called cutaneous T-cell lymphoma, or CTCL. CTCL is a cancer of white blood cells that appears in the skin. The most common type is mycosis fungoides. A more advanced type is Sézary syndrome.
Here is the part that matters. In its early stages, CTCL looks almost exactly like eczema. Red, itchy, scaly patches. It is routinely mistaken for eczema for years. Diagnosis usually comes only from a skin biopsy.
Some claims argue that suppressing part of the immune system allowed a T-cell cancer to develop. One study in Dermatologic Therapy reported a substantially higher relative risk of CTCL in eczema patients treated with dupilumab compared with those who were not.
Other claims argue the lymphoma was already there, undiagnosed as eczema. The drug eased the symptoms, so nobody ordered the biopsy. The cancer kept growing while the rash looked better.
A third group of claims argues that in patients who already had CTCL, the drug accelerated it. Reports along these lines have appeared in the Journal of the American Academy of Dermatology. All three theories share the same legal core: that Sanofi and Regeneron should have warned patients and doctors about the risk, and did not.
If you are on Dupixent and your rash is changing — spreading, thickening, forming raised patches, or not responding the way it used to — tell your dermatologist and ask whether a skin biopsy is appropriate. That is a conversation worth having regardless of any lawsuit. Do not stop or change treatment based on what you read here.
— Compensation
If a claim succeeds, compensation is meant to cover what the illness has cost you — in money, in work, and in life. Here is what these claims typically seek.
— The process
You do not need your records or exact dates to start. Tell us what you remember and the firm does the rest.
Fill out the short form or call. What you took Dupixent for, roughly when you started, and what you were diagnosed with. It takes about two minutes. There is no cost and no obligation.
If your situation fits, we connect you with a participating law firm. That firm looks at your case on its own and decides whether to represent you. If it does, you sign an agreement directly with the firm.
Dermatology notes, pharmacy records, biopsy and pathology reports. In these cases the timeline is the case, and pathology review is often what decides whether a firm takes it.
Your case is filed and coordinated in MDL 3180. Your firm keeps you updated as the court sets its schedule. You are never required to accept an offer you do not want.
💰
⚖️
What Direct2Attorney is
A legal marketing and referral service. We check whether your situation matches what participating law firms are looking for, and connect you with one of them if it does.
What Direct2Attorney is not
We are not a law firm. We cannot give you legal advice, represent you, or file anything on your behalf. Only a law firm you sign with can do that.
Did you take Dupixent and later get diagnosed with cutaneous T-cell lymphoma, mycosis fungoides or Sézary syndrome? Find out where you stand. It takes about two minutes and costs nothing. Your state’s filing deadline is running whether or not you look into it — and asking a lawyer never changes your medical treatment.
— QUESTIONS
Participating law firms are generally reviewing claims from people who took Dupixent and were later diagnosed with cutaneous T-cell lymphoma, mycosis fungoides or Sézary syndrome. The diagnosis usually needs to come after starting the drug and be confirmed by a skin biopsy. Family members may be able to bring a wrongful death claim for a loved one who died.
Do not stop on your own. Dupixent controls serious conditions for millions of people, and stopping suddenly can cause severe flares or, for asthma patients, a dangerous attack. Nothing on this page is medical advice. If you are worried, call your prescribing doctor and ask. That is a medical decision between you and your physician, and it is completely separate from any legal question.
Cutaneous T-cell lymphoma, or CTCL, is a rare cancer of white blood cells that shows up in the skin. The most common form is mycosis fungoides. A more advanced form is Sézary syndrome. In its early stages CTCL can look almost exactly like eczema, which is why it is often misdiagnosed for years before a skin biopsy identifies it.
On June 4, 2026 federal cases were centralized into MDL No. 3180, In re: Dupixent (Dupilumab) Products Liability Litigation, in the District of New Jersey before Judge Zahid N. Quraishi. The litigation began with 15 cases from 12 districts plus 7 potential tag-along actions. There is no settlement, no trial date and no verdict. This is a very new litigation.
That may still support a claim, and it is one of the main arguments in this litigation. Early CTCL looks like stubborn eczema, so some patients were treated with Dupixent when the cancer was already present but undiagnosed. Claims argue the drug eased the symptoms while the disease kept progressing, delaying the biopsy that would have found it. A firm reviewing your records looks at the timeline either way.
Nothing to ask. The case review is free with no obligation. If a participating law firm takes your case, it will normally work on contingency. That means the fee comes out of a recovery, and no fee is owed if there is no recovery.
No. Direct2Attorney is a legal marketing and referral service, not a law firm. An attorney-client relationship may form only after a participating law firm reviews your information and signs a separate representation agreement with you.
Ask it on the call. The review is free, and there is no obligation to move forward.
— News & updates
monitored after approval. Although Dupixent is widely prescribed for eczema, asthma, and nasal polyps, the FDA continues to track its
Emerging Lawsuits and Current Filings Over the past few months, more people have started filing lawsuits against the makers of
